Aktuellt
SENASTE
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) has entered into a transformational phase, with a clear focus on diversifying the customer base through increased marketing and sales efforts. Looking ahead, this is estimated to result in a period of inhibited sales growth, however, Analyst Group sees this as vital in the long run, as the customer concentration risk is expected to decrease significantly. Analyst Group estimates a turnover of EUR 8.9m by 2024, and with an applied EV/S multiple of 1.0x, a potential present value per share of 2.4 (4.9) is derived in a Base scenario.
LÄS MER
